BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Overton LC, Heinrich MC. Regorafenib for treatment of advanced gastrointestinal stromal tumors. Expert Opin Pharmacother. 2014;15:549-558. [PMID: 24405315 DOI: 10.1517/14656566.2014.877888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Shao J, Markowitz JS, Bei D, An G. Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 2014;103:3810-33. [DOI: 10.1002/jps.24113] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
2 Xu C, Li W, Qiu P, Xia Y, Du X, Wang F, Shen L, Chen Q, Zhao Y, Jin R, Wu J, Liang G, Li X. The therapeutic potential of a novel non-ATP-competitive fibroblast growth factor receptor 1 inhibitor on gastric cancer. Anti-Cancer Drugs 2015;26:379-87. [DOI: 10.1097/cad.0000000000000195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
3 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, González-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med 2019;51:1-15. [PMID: 31551425 DOI: 10.1038/s12276-019-0308-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
4 Gunaratnam M, Collie GW, Reszka AP, Todd AK, Parkinson GN, Neidle S. A naphthalene diimide G-quadruplex ligand inhibits cell growth and down-regulates BCL-2 expression in an imatinib-resistant gastrointestinal cancer cell line. Bioorganic & Medicinal Chemistry 2018;26:2958-64. [DOI: 10.1016/j.bmc.2018.04.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
5 Zemła P, Stelmach A, Jabłońska B, Gołka D, Mrowiec S. A Retrospective Study of Postoperative Outcomes in 98 Patients Diagnosed with Gastrointestinal Stromal Tumor (GIST) of the Upper, Middle, and Lower Gastrointestinal Tract Between 2009 and 2019 at a Single Center in Poland. Med Sci Monit 2021;27:e932809. [PMID: 34645778 DOI: 10.12659/MSM.932809] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rutkowski P, Stępniak J. The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Expert Opin Drug Saf 2016;15:105-16. [PMID: 26651387 DOI: 10.1517/14740338.2016.1122754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
7 Zhu JQ, Ou WB. Therapeutic targets in gastrointestinal stromal tumors. World J Transl Med 2015; 4(1): 25-37 [DOI: 10.5528/wjtm.v4.i1.25] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Zhu N, Xiao H, Wang LM, Fu S, Zhao C, Huang H. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies. Future Oncol 2015;11:659-73. [PMID: 25686120 DOI: 10.2217/fon.14.280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
9 Wang L, Du B, Zuo D, Cheng M, Zhao M, Zhao S, Zhai X, Gong P. An efficient and high-yielding protocol for the production of Regorafenib via a new synthetic strategy. Res Chem Intermed 2016;42:3209-18. [DOI: 10.1007/s11164-015-2206-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Rutkowski P, Jagielska B, Andrzejuk J, Bylina E, Lugowska I, Switaj T, Kosela-Paterczyk H, Kozak K, Falkowski S, Klimczak A. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemp Oncol (Pozn) 2017;21:285-9. [PMID: 29416434 DOI: 10.5114/wo.2017.72393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Prause M, Niedermoser S, Wängler C, Decristoforo C, Seibold U, Riester S, Taguchi T, Schirrmacher R, Fricker G, Wängler B. Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. Nucl Med Biol 2018;57:1-11. [PMID: 29175467 DOI: 10.1016/j.nucmedbio.2017.11.004] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]